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Problem Identification and description
of need


In order to best provide preventative healthcare to the population, it is important for providers to be
aware of vaccination guidelines and advocate for patient compliance to reduce morbidity and
mortality. In the last 5 years, there have been significant changes in Tdap vaccination recommendations
in pregnancy.



Prior to June 2011, the Advisory Committee on Immunizations Practices (ACIP) recommended Tdap
vaccination to be given to women postpartum.1 Beginning June 2011, guidelines also endorsed
vaccination during pregnancy if the woman had not received Tdap before. 1



However, data has been found that Tdap vaccination between 27 and 36 weeks of pregnancy most
effectively boosts IgG placental transmission to the fetus and results in longer lasting detection of
antibody presence after birth.2,3 As a corollary, maternal vaccination during this critical time period has
the potential to reduce risk of infant morbidity and mortality. In October 2012, ACIP guidelines changed
to recommend vaccination between 27 and 36 weeks of every pregnancy to augment IgG placental
transfer to the fetus, irrespective of previous vaccination status.1



Maternal Tdap vaccination has been proven to be safe to the fetus during pregnancy and yet not all
pregnant women receive the immunization.4



A review of 16 States found overall Tdap vaccination rates before, during, and after pregnancy ranged
from 38.2% to 76.6% from September 2011 to December 2011. 1 Of these states, Maine was found to have
a vaccination rate of 66.2%. 1



In one Tdap vaccination attitudes survey, 89% women reported they would get the Tdap vaccination
during pregnancy if their physician advocated the immunization.5 Thus, it is important for physicians to be
aware of the updated guidelines and to directly advocate vaccination for every pregnant woman.
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Public Health Cost & Unique Cost
considerations in host community


In 2014, there were 13 reported deaths related to pertussis and 8 of these were in the
immunologically vulnerable population of infants less than 3 months old.6



Approximately half of infants less than one year old infected with pertussis require hospitalization.2
Of the cohort hospitalized, 23% develop pneumonia and 1.6% die.2



It is particularly important to be cognizant of pertussis risks in Maine as the state has the second
highest rate of pertussis in the USA with incidence of 41.9 per 100,000.6



Per previous chart reviews performed by Dr. Robin Pritham, Medical Director at Eastern Maine
Medical Center (EMMC) Family Medicine Center and Residency, Tdap vaccination in pregnancy
compliance ranged 76-90% with overall 80% vaccinated between a sampling of dates between
September 2014 to September 2015 at the family medicine outpatient clinic.

History of EMMC Family Medicine Center and Residency Maternal Tdap Vaccination Compliance
Percent
Date
Deliveries Tdap Vaccinated Offered and Declined Not Documented Vaccinated
January 2014-March 2014
53
42
11
0
September 2014-January 2015
80
61
19
0
May 2015-June 2015
32
29
3
0
July *Table
2015-September
2015
41
33
8
0
data obtained from Dr. Robin Pritham, personal communication
Total:
206
165
41
0

79%
76%
90%
80%
80%
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Community perspective on issue &
support for project
 Dr. Nina Quicksell, DO PGY-2
 What is your perception of the EMMC Family Medicine Center and Residency’s compliance
of the ACIP guideline to administer Tdap in the third trimester of pregnancy? “Most patients
get it, the problem is getting the medical assistant staff to remember to remind us.”
 How do you think providers weigh maternal Tdap vaccination importance? “Providers are
not considering the Tdap vaccination unless it is brought up because so many other things
are going on, we lose focus.”
 What are the barriers to compliance with guidelines to vaccinate pregnant women with
Tdap? “A lot of it is providers not bringing it up.”
 How are residents trained on Tdap in the third trimester of pregnancy guidelines? “Through
rotations in OB and here [at the EMMC Family Medicine Center and Residency]; also
through the ALSO course.”
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Community perspective on issue &
support for project
 Christie Brown, FNP
 How are providers trained on Tdap in the third trimester of pregnancy guidelines? “We use
the immunization schedules posted on personal electronic devices/CDC website. Tdap in
pregnancy training was topic of discussion around clinic when guidelines came out.
Discussed at staff meetings.”

 Are providers reminded to vaccinate with Tdap during pregnancy? “Charts are reviewed
by the clinical nurse manager and support staff and reminders to immunize are placed in
the appointment summary line.”
 How do you think EMMC Family Medicine Center and Residency could improve patient
compliance with vaccination recommendations? “Perhaps begin educating about safety
of immunizations at prenatal screening/intake.”
 Why do you think patients refuse Tdap in pregnancy? “I think they are afraid of needles.”
 How do you respond when a pregnant patient states they do not want the vaccination?
“Ask them to reconsider, to do independent research and come back with questions.”
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Intervention & Methodology


Goal: To assess EMMC Family Medicine Center and Residency’s maternal Tdap vaccination rates
and distribute an educational handout for quality improvement.



Methodology: A data report was generated through electronic medical records (EMR) search
utilizing the same methods of previous EMMC Family Medicine Center and Residency quality
improvement reviews of maternal Tdap vaccination rates. To generate the number of
pregnancies within the time frame, the EMR was searched with parameters that included women
with an estimated due date between February 1st 2016 and August 1st 2016. To determine
numbers of those vaccinated, a second parameter was added selecting patients who had
documented Tdap vaccination between August 1st 2015 and August 1st 2016. Within the
unvaccinated group, the patients with documented refusal in the EMR were classified as
documented Tdap refusal. The remaining number of patients were placed into the
undocumented, unvaccinated group.



Intervention: To communicate clinic compliance rates and provide a reminder of the importance
of maternal Tdap vaccination, I decided to create an educational handout including high-yield
points about pertussis and this project’s data report findings (see appendix A). This handout was
e-mailed to EMMC Family Medicine Center and Residency’s provider, resident, and clinical
support staff listservs. Further, the handout was posted in the nursing documentation room, office
break room, on two bulletin boards, and in physician preceptor room for total of 5 locations
around office. Finally, physical copies of the handout were placed in all of the residents
mailboxes.

Results/Response
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EMMC Family Medicine and Residency Tdap in Pregnancy Compliance:
February to August 2016

 72 (78%) were vaccinated

Vaccinated

13%
9%

 8 (9%) were documented refusals

Documented
Vaccination Refusal

78%

 92 eligible pregnancies discovered:

Undocumented

 12 (13%) were not documented as given or offered in
the EMR

 Vaccination rates were found to be consistent with
previous data of overall 80% compliance at sporadic
periods of data review January 2014 to September
2015.

Comparison of Maternal Tdap Vaccination Rates at Various
Time Periods

90%

 Surprisingly, there were 8 undocumented cases in the
dates reviewed compared to no undocumented
cases in dates previously analyzed by Dr. Robin
Pritham.
 Educational handout developed (appendix A):

79%

80%
76%

78%

January 2014- September 2014- May 2015-June
July 2015February 2016March 2014
January 2015
2015
September 2015 August 2016

 Posted in 5 non-patient areas in the EMMC Family
Medicine Center and Residency office
 Distributed paper copy to all resident mailboxes
 E-mailed out to clinic faculty, providers, residents, and
clinical support staff
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Evaluation of Effectiveness &
Limitations


Limitations:
 The computerized data report could not individually pick out what week of the pregnancy the
Tdap was given for each patient but instead assessed for vaccination during the August 2015 to
August 2016 time frame. As a result, there is the potential that some of the numbers counted as
vaccinated may have had it administered outside the 27 to 36 weeks recommended time period
but otherwise during or closely around pregnancy.
 Since the search only evaluated entries on the EMR flowsheet and immunization administration
record, undocumented numbers may have been falsely inflated due to the possibility of patients
being vaccinated outside the EMMC system. The undocumented rate may have also been inflated
if providers simply typed in notes that the vaccination was refused instead of adding it into the
flowsheet.



Evaluation of effectiveness:
 The handout educated faculty, providers, residents, and clinical support staff of the clinic’s
maternal Tdap administration rates, ACIP guidelines, and rationale for vaccination.
 In order to evaluate effectiveness of the handout on vaccination rates, several months would have
to pass after project completion to accumulate an adequate sample of pregnant women. This was
not feasible due to the time constraint of a 5-week rotation in Bangor, ME.
 However, several providers gave positive feedback that the handout was a helpful reminder; two
directly reported that they wanted to use the information to reach out to patients and/or clinical
care staff.
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Recommendations for the Future
 Documentation of Tdap refusal could be improved by scheduled, regular reminders to
providers and clinical support staff during the weekly office huddles.
 Provider awareness of maternal Tdap vaccination compliance could be raised by
increasing data report frequency to bimonthly and having subsequent discussions of Tdap
vaccination rates in the office huddles for each report.
 For future projects, more accurate and in-depth data could be obtained with a chart
review to determine exactly what weeks of pregnancy patients received the Tdap
vaccination. Also, a thorough chart review could determine if there are trends based on
training background or provider’s level of experience being associated with lower or
higher vaccination rates.

 The office plans to add a check box to pregnancy intake forms that most providers fill out
for each pregnancy visit. When this is completed, future projects could repeat these
methods to see how maternal Tdap vaccination compliance compares before and after
the intervention.

9

References
1.

Ahluwalia, I.B., Ding, H., D’Angelo, D., Shealy, K.H., Singleton, J.A., Liang, J., and Rosenburg, K.D.
(2015, May 22). CDC Morbidity and Mortality Weekly Report. Tetanus, Diphtheria, Pertussis
Vaccination Coverage Before, During, and After Pregnancy — 16 States and New York City, 2011.
Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6419a4.htm

2.

Maine Center for Disease Control and Prevention (2014, November). Tdap for Pregnant Women.
Retrieved from http://www.maine.gov/dhhs/mecdc/infectiousdisease/immunization/providers/communications/2014/November-newsletter.pdf

3.

Vilajeliu, A., Ferrer, L., Munrós, J., Goncé, A., López, M., et al. (2016, July 19). Pertussis vaccination
during pregnancy: Antibody persistence in infants. Vaccine 34(33):3719-22. doi:
10.1016/j.vaccine.2016.05.051

4.

Walls, T., Graham, P., Petousis-Harris, H., Hill, L., and Austin, N. (2016, January 6). Infant outcomes
after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open 6(1). doi:
10.1136/bmjopen-2015-009536

5.

MacDougall, D.M., Halperin, B.A., Langley, J.M., McNeil, S.A., MacKinnon-Cameron, D., Li, L., and
Halperin, S.A. (2016, April 2). Knowledge, attitudes, beliefs, and behaviors of pregnant women
approached to participate in a Tdap maternal immunization randomized, controlled trial. Human
Vaccines and Immunotherapeutics, 12(4):879-85. doi: 10.1080/21645515.2015.1130193.

6.

National Center for Immunization and Respiratory Disease (2015, October). 2014 Final Pertussis
Surveillance Report. Retrieved from https://www.cdc.gov/pertussis/downloads/pertuss-surv-report2014.pdf

10

Interview Consent


Thank you for agreeing to be interviewed. This project is a requirement for the Family Medicine
clerkship. It will be stored on the Dana Library ScholarWorks website. Your name will be attached
to your interview and you may be cited directly or indirectly in subsequent unpublished or
published work.



The interviewer affirms that he/she has explained the nature and purpose of this project.



The interviewee affirms that he/she has consented to this interview.



Yes __X__



Name: ___Christie Brown, FNP__________________________________________



Name: ___Nina Quicksell, DO PGY-2_____________________________________

Appendix A:

Educational handout
• Posted in 5 non-patient
areas in the EMMC
Family Medicine Center
and Residency office
• Distributed to all resident
mailboxes
• E-mailed out to clinic
faculty, providers,
residents, and clinical
support staff

